Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Alexandre, Hertz Daniel L, Morales Manuel, Adams Elizabeth J, Gordon Sharon, Tan Chia Jie, Staff Nathan P, Kamath Jayesh, Oh Jeong, Shinde Shivani, Pon Doreen, Dixit Niharkia, D'Olimpio James, Dumitrescu Cristina, Gobbo Margherita, Kober Kord, Mayo Samantha, Pang Linda, Subbiah Ishwaria, Beutler Andreas S, Peters Katherine B, Loprinzi Charles, Lustberg Maryam B
Аннотация
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.